Literature DB >> 7609068

Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase.

J Cooper1, J Conner, J B Clements.   

Abstract

We have compared the protein kinase activities of the R1 subunits from herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) ribonucleotide reductase following expression in Escherichia coli. Autophosphorylation activity was observed when kinase assays were performed with immunoprecipitated R1 or proteins purified to homogeneity, and the activity was stimulated by the basic protein protamine. Transphosphorylation of histones or calmodulin by purified or immunoprecipitated HSV-1 and HSV-2 R1 was not observed, and our results suggest that the activities of these two proteins are similar. We further characterized the protein kinase activity of HSV-1 R1 by producing insertion and deletion mutants constructed with a plasmid expressing R1 amino acids 1 to 449. C-terminal deletion analysis identified the catalytic core of the enzyme as comprising residues 1 to 292, and this polypeptide will be useful for structural determinations by X-ray crystallography. Insertion of a 4-amino-acid sequence at sites within the protein kinase domain identified regions essential for activity; insertions at residues 22 and 112 completely inactivated activity, and an insertion at residue 136 reduced activity sixfold. Similar insertions at residues 257, 262, 292, and 343 had no effect on activity. The ATP analog 5'-fluorosulfonylbenzoyladenosine, which covalently modifies conventional eukaryotic kinases at an essential lysine residue within the active site, did label HSV R1, but this labelling occurred outside the N-terminal domain. These data indicate that the HSV R1 kinase is novel and distinct from other eukaryotic protein kinases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609068      PMCID: PMC189314          DOI: 10.1128/JVI.69.8.4979-4985.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Myristylation and polylysine-mediated activation of the protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).

Authors:  T D Chung; J P Wymer; M Kulka; C C Smith; L Aurelian
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

2.  Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2.

Authors:  J P Wymer; T D Chung; Y N Chang; G S Hayward; L Aurelian
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).

Authors:  T D Chung; J P Wymer; C C Smith; M Kulka; L Aurelian
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

4.  Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.

Authors:  J M Cameron; I McDougall; H S Marsden; V G Preston; D M Ryan; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

5.  The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 beta 2 composed of 40K and 140K proteins, of which the latter shows multiple forms due to proteolysis.

Authors:  R Ingemarson; H Lankinen
Journal:  Virology       Date:  1987-02       Impact factor: 3.616

6.  A single amino acid substitution in the large subunit of herpes simplex virus type 1 ribonucleotide reductase which prevents subunit association.

Authors:  I Nikas; A J Darling; H M Lankinen; A M Cross; H S Marsden; J B Clements
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

7.  A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.

Authors:  J G Jacobson; D A Leib; D J Goldstein; C L Bogard; P A Schaffer; S K Weller; D M Coen
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

8.  The large subunit of herpes simplex virus type 1 ribonucleotide reductase: expression in Escherichia coli and purification.

Authors:  J Furlong; J Conner; J McLauchlan; H Lankinen; C Galt; H S Marsden; J B Clements
Journal:  Virology       Date:  1991-06       Impact factor: 3.616

9.  Structural features of ribonucleotide reductase.

Authors:  I Nikas; J McLauchlan; A J Davison; W R Taylor; J B Clements
Journal:  Proteins       Date:  1986-12

Review 10.  The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; M A Dalrymple; A J Davison; A Dolan; M C Frame; D McNab; L J Perry; J E Scott; P Taylor
Journal:  J Gen Virol       Date:  1988-07       Impact factor: 3.891

View more
  9 in total

1.  Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts.

Authors:  D Lembo; G Gribaudo; A Hofer; L Riera; M Cornaglia; A Mondo; A Angeretti; M Gariglio; L Thelander; S Landolfo
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.

Authors:  David J Davido; Eleain M Tu; Hong Wang; Maria Korom; Andreu Gazquez Casals; P Jahnu Reddy; Heba H Mostafa; Benjamin Combs; Steve D Haenchen; Lynda A Morrison
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

3.  Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation.

Authors:  Heba H Mostafa; Thornton W Thompson; Adam J Konen; Steve D Haenchen; Joshua G Hilliard; Stuart J Macdonald; Lynda A Morrison; David J Davido
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  A short polypeptide from the herpes simplex virus type 2 ICP10 gene can induce antigen aggregation and autophagosomal degradation for enhanced immune presentation.

Authors:  Xinping Fu; Lihua Tao; Xiaoliu Zhang
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

5.  Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth.

Authors:  C C Smith; J Nelson; L Aurelian; M Gober; B B Goswami
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Herpes simplex virus type 1-induced encephalitis has an apoptotic component associated with activation of c-Jun N-terminal kinase.

Authors:  Dana Perkins; Kymberly A Gyure; Edna F R Pereira; Laure Aurelian
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

7.  The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.

Authors:  D Perkins; E F R Pereira; M Gober; P J Yarowsky; L Aurelian
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.

Authors:  L M Schang; J Phillips; P A Schaffer
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth.

Authors:  C C Smith; T Peng; M Kulka; L Aurelian
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.